263 related articles for article (PubMed ID: 35386181)
1. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.
Kassis-George H; Verlinden NJ; Fu S; Kanwar M
Ther Clin Risk Manag; 2022; 18():315-322. PubMed ID: 35386181
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
3. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Coats AJS; Tolppanen H
Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
Butler J; Usman MS; Anstrom KJ; Blaustein RO; Bonaca MP; Ezekowitz JA; Freitas C; Lam CSP; Lewis EF; Lindenfeld J; McMullan CJ; Mentz RJ; O'Connor C; Rosano GMC; Saldarriaga CI; Senni M; Udelson J; Voors AA; Zannad F
Eur J Heart Fail; 2022 Nov; 24(11):2029-2036. PubMed ID: 36250238
[TBL] [Abstract][Full Text] [Related]
5. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Kang C; Lamb YN
Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
[TBL] [Abstract][Full Text] [Related]
6. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
7. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
[TBL] [Abstract][Full Text] [Related]
8. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
9. Emerging concepts in heart failure management and treatment: focus on vericiguat.
Kaplinsky E; Perrone S; Barbagelata A
Drugs Context; 2023; 12():. PubMed ID: 36660012
[TBL] [Abstract][Full Text] [Related]
10. Vericiguat for the treatment of heart failure with reduced ejection fraction.
Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
[TBL] [Abstract][Full Text] [Related]
11. Vericiguat for Heart Failure with Reduced Ejection Fraction.
Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Role of Vericiguat in Patients With Chronic Heart Failure.
Dies RM; Jackson CN; Flanagan CJ; Sinnathamby ES; Spillers NJ; Potharaju P; Singh N; Varrassi G; Ahmadzadeh S; Shekoohi S; Kaye AD
Cureus; 2023 Dec; 15(12):e49782. PubMed ID: 38161537
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M
J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741
[TBL] [Abstract][Full Text] [Related]
14. The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.
Cordwin DJ; Berei TJ; Pogue KT
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):593-600. PubMed ID: 34487435
[TBL] [Abstract][Full Text] [Related]
15. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
[TBL] [Abstract][Full Text] [Related]
16. Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications.
Vannuccini F; Campora A; Barilli M; Palazzuoli A
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289733
[TBL] [Abstract][Full Text] [Related]
17. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction.
Tran BA; Serag-Bolos ES; Fernandez J; Miranda AC
J Pharm Pract; 2023 Aug; 36(4):905-914. PubMed ID: 35356844
[No Abstract] [Full Text] [Related]
18. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
Trujillo ME; Ayalasomayajula S; Blaustein RO; Gheyas F
Clin Transl Sci; 2023 Dec; 16(12):2458-2466. PubMed ID: 37997225
[TBL] [Abstract][Full Text] [Related]
19. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure].
Belenkov YN; Kozhevnikova MV
Kardiologiia; 2023 May; 63(5):68-76. PubMed ID: 37307211
[TBL] [Abstract][Full Text] [Related]
20. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
